Adverum Stock Analysis

The new indifference towards the small price fluctuations of Adverum Biotechnlgs could raise concerns from stakeholders as the firm is trading at a share price of 0.0 on very low momentum in volume. The company directors and management did not add any value to Adverum Biotechnlgs investors in September. However, most investors can still diversify their portfolios with Adverum Biotechnlgs to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to stakeholders with longer-term investment horizons.
Check out Trending Equities.
The Adverum Biotechnlgs stock analysis report makes it easy to digest most publicly released information about Adverum Biotechnlgs and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Adverum Stock analysis module also helps to analyze the Adverum Biotechnlgs price relationship with some important fundamental indicators such as market cap and management efficiency.

Adverum Stock Analysis Notes

About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.21. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnlgs recorded a loss per share of 1.38. The entity had not issued any dividends in recent years. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people. For more info on Adverum Biotechnlgs please contact Paul Cleveland at 650 656 9323 or go to

Adverum Biotechnlgs Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Adverum Biotechnlgs' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Adverum Biotechnlgs or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Adverum Biotechnlgs is not yet fully synchronised with the market data
Adverum Biotechnlgs has some characteristics of a very speculative penny stock
Adverum Biotechnlgs has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 7.5 M. Net Loss for the year was (155.01 M) with loss before overhead, payroll, taxes, and interest of (81.68 M).
Adverum Biotechnlgs currently holds about 271.06 M in cash with (114.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.74.
Roughly 70.0% of the company shares are held by institutions such as insurance companies

Adverum Biotechnlgs Upcoming and Recent Events

Earnings reports are used by Adverum Biotechnlgs to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adverum Biotechnlgs previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Adverum Biotechnlgs SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Adverum Biotechnlgs prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Adverum Biotechnlgs investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Adverum Biotechnlgs specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of September 2022
Unclassified Corporate Event
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
8th of July 2022
Unclassified Corporate Event
6th of July 2022
Cost Associated with Exit or Disposal Activities
16th of June 2022
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
6th of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
12th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of May 2022
Unclassified Corporate Event

Adverum Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Adverum Biotechnlgs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adverum Biotechnlgs backward and forwards among themselves. Adverum Biotechnlgs' institutional investor refers to the entity that pools money to purchase Adverum Biotechnlgs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares10.9 M13 M
Morgan StanleyCommon Shares7.4 M8.8 M
Sonic Fund Ii LpCommon Shares6.6 M7.9 M
Versant Venture Management LlcCommon Shares5.1 M6.1 M
Vanguard Group IncCommon Shares4.2 MM
Blackrock IncCommon Shares3.3 MM
Artal Group SaCommon SharesM3.6 M
Group One Trading LpCall Options841 KM
Note, although Adverum Biotechnlgs' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adverum Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 93.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adverum Biotechnlgs's market, we take the total number of its shares issued and multiply it by Adverum Biotechnlgs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (22.23) % which means that it has lost $22.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (44.43) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnlgs management efficiency ratios could be used to measure how well adverum biotechnlgs manages its routine affairs as well as how well it operates its assets and liabilities.

Adverum Biotechnlgs Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnlgs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnlgs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnlgs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Adverum Biotechnlgs Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Adverum Biotechnlgs to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Theme Ratings Now


Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
Check out Trending Equities. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Tools for Adverum Stock

When running Adverum Biotechnlgs price analysis, check to measure Adverum Biotechnlgs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnlgs is operating at the current time. Most of Adverum Biotechnlgs' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnlgs' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adverum Biotechnlgs' price. Additionally, you may evaluate how the addition of Adverum Biotechnlgs to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes